Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3

Table 1 Hemodynamics

	Baseline	Pre-occlusion	Ischemia	Reperfusion
			30 min	2 h
Heart rate, beats ^-1
WT Control	430 ± 26	426 ± 26	383 ± 39*^#	363 ± 26*^#
WT Ex-4	432 ± 16	413 ± 41	402 ± 16	398 ± 9
Cav-3 KO Control	413 ± 27	415 ± 25	383 ± 25	381 ± 32
Cav-3 KO Ex-4	416 ± 28	419 ± 26	376 ± 39	357 ± 36*^#
Mean arterial pressure, mmHg
WT Control	75 ± 6	75 ± 6	70 ± 6	65 ± 10*^#
WT Ex-4	78 ± 5	75 ± 5	72 ± 7 70 ± 8
Cav-3 KO Control	77 ± 4	75 ± 4	71 ± 3* 65 ± 6*^#
Cav-3 KO Ex-4	76 ± 5	75 ± 5	70 ± 3	66 ± 5*^#
Rate-Pressure Product, beats min^-1mmHg 10³
WT Control	32.0 ± 3.3	32.0 ± 1.4	26.7 ± 3.5*^#	23.7 ± 4.7*^#
WT Ex-4	33.6 ± 2.7	31.2 ± 4.1	29.2 ± 3.5	28.0 ± 3.6*
Cav-3 KO Control	31.9 ± 2.2	31.1 ± 2.6	27.0± 2.3*^#	25.0± 3.5*^#
Cav-3 KO Ex-4	31.5± 3.7	31.5± 3.2	26.4± 3.5*^#	23.4± 2.6*^#

Data are mean ± SD. Wild-type (WT) or caveolins-3 knockout (Cav-3 KO) mice were randomly exposed to exendin-4 (Ex-4).
^*Significantly (P < 0.05) different from baseline (intragroup comparison).
^#Significantly (P < 0.05) different from pre-occlusion (intragroup comparison).

ISSN: 1475-2840